Publications
Discover our latest research and scientific contributions, showcasing the work we do to advance knowledge and develop new approaches to treatment
The Novel SSTR3 Full Agonist ITF2984 Shows Antitumor Properties against Pancreatic Neuroendocrine Tumors
ITF2984, a novel SSTR3-targeting multireceptor agonist, shows comparable or enhanced antiproliferative, pro-apoptotic, and antisecretory effects versus pasireotide in pancreatic NET models.
These findings highlight its potential as an alternative targeted therapy for SSTR3-expressing tumors, including advanced Pan-NETs.
Anti-secretory and anti-proliferative actions of next-generation dual subtype 2 and 5 somatostatin receptor ligands in neuroendocrine tumor models
Novel dual SSTR2/SSTR5 agonists (SMTR-001–005) demonstrate antisecretory and antiproliferative effects comparable or superior to current somatostatin analogs in preclinical neuroendocrine tumor models.
These findings support their development as next-generation targeted therapies for SSTR2/5-expressing tumors.
Tribbles Genes in Gastric Cancer: A Tumor-Suppressive Role for TRIB2
TRIB2 displays a tumor-suppressive role in chromosomal instability gastric cancer, with low expression associated with advanced disease and increased tumor aggressiveness.
These findings identify TRIB2 as a potential biomarker and therapeutic target in gastric cancer.